Ajinomoto Co., Inc.

Exhibitor

Ajinomoto Co., Inc. dba Ajinomoto Bio-Pharma Services is a global CDMO offering cutting-edge ADC technologies and high-quality and scalable manufacturing capabilities for various modalities such as oligonucleotides, PMO, peptides, VHH, small molecules and AAV for gene therapy. With our over decades expertise, we can support the entire lifecycle of your program from preclinical to commercial supply.

[Summary of our Services / Platform Technologies]

AJICAP®: Site-specific ADC conjugation and linker technology that requires neither genetic modifications nor enzymes. Ajinomoto developed an innovative "chemical" site-selective conjugation method of Fc moiety in intact antibody. This technology provides significant advantages for next generation ADCs; 1) Straightforward CMC - Direct modification of intact antibody. - No genetic modification / no enzyme required, 2) Enhancement of Therapeutic Window compared to stochastic ADCs - Site specific DAR 1, 2, 4 or higher and Dual Payload are available, 3) Wide drug-linker compatibility: reactive group compatibility including thiol and azide. 4) High yields, short conjugation reaction times, ease to manufacture. AJICAP can also be utilized for other modalities besides ADCs such as Antibody Oligonucleotide Conjugates, LNP Conjugates, Peptide Conjugates and Aptamar Conjugates.

CORYNEX®, non-endotoxic microbial secretion system based on gram positive C. glutamicum for Long-chain peptides, VHH (Nanobodies), and Antibody mimetics (scaffolds). Main advantages of CORYNEX® compared to solid phase is its applicability towards long-chain peptides, scalability, and sustainability. Main advantages compared to E. coli is its lack of endotoxins and its ability to secrete active proteins directly into the media with high titers and purity.

AJIPHASE®, Innovative liquid phase synthesis for oligonucleotide, peptide, PMO and PPMO. Mass Production with High Purity. Achieved by hybrid process of conventional solid phase and classical liquid phase synthesis technology. Seamless Scale Up from Lab to Commercial. Highly-repeatable process with no special equipment. Convergent synthesis with enzyme realizes greener and productive process than the commonly used technology. Especially for long RNAs such as 100-800mer, chemical&biological hybrid procedure can induce unnatural RNA modification freely. It enables you to explore new RNA therapy area.

website